SRR817978
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.531
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- IL6_JAK_STAT3_SIGNALING+0.367
- INFLAMMATORY_RESPONSE+0.364
- ANGIOGENESIS+0.361
- INTERFERON_GAMMA_RESPONSE+0.298
- MYOGENESIS+0.292
- HYPOXIA+0.287
- KRAS_SIGNALING_DN+0.285
- ESTROGEN_RESPONSE_EARLY+0.283
Top 10 suppressed
- E2F_TARGETS-0.415
- DNA_REPAIR-0.360
- G2M_CHECKPOINT-0.354
- MYC_TARGETS_V1-0.329
- PROTEIN_SECRETION-0.312
- WNT_BETA_CATENIN_SIGNALING-0.238
- MITOTIC_SPINDLE-0.198
- MYC_TARGETS_V2-0.140
- BILE_ACID_METABOLISM-0.075
- CHOLESTEROL_HOMEOSTASIS-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1388979 | GTEX | — | 0.917 |
| 2 | SRR820883 | GTEX | — | 0.889 |
| 3 | SRR1472394 | GTEX | — | 0.882 |
| 4 | SRR1471903 | GTEX | — | 0.874 |
| 5 | SRR1381543 | GTEX | — | 0.873 |
| 6 | ERR2598287 | fetal | fetal | 0.866 |
| 7 | SRR1489177 | GTEX | — | 0.864 |
| 8 | SRR818110 | GTEX | — | 0.852 |
| 9 | SRR663693 | GTEX | — | 0.852 |
| 10 | SRR598332 | GTEX | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.531 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.367 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.364 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.361 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.298 | Idelalisib | — uncovered |
| MYOGENESIS | 0.292 | Inavolisib | — uncovered |
| HYPOXIA | 0.287 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.285 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.283 | Inavolisib | — uncovered |
| COAGULATION | 0.264 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.261 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.231 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.224 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.207 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.207 | Inavolisib | — uncovered |
| APOPTOSIS | 0.182 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.175 | Inavolisib | — uncovered |
| COMPLEMENT | 0.171 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |